Won et al. (27) reported that 4.4% of patients with ALK-positive NSCLC have EGFR concomitant mutation using Sanger sequencing, and this rose to 15.4% of patients when using NGS. This evidence concerns the gene ALK and non-small cell lung carcinoma.